Comparison of the Effects of Ezetimibe-Statin Combination Therapy on Major Adverse Cardiovascular Events in Patients with and without Diabetes: A Meta-Analysis

Endocrinology and Metabolism
Namki HongEun Seok Kang

Abstract

Ezetimibe-statin combination therapy has been found to reduce low density lipoprotein cholesterol levels and the risk of major adverse cardiovascular events (MACEs) in large trials. We sought to examine the differential effect of ezetimibe on MACEs when added to statins according to the presence of diabetes. Randomized clinical trials with a sample size of at least 50 participants and at least 24 weeks of follow-up that compared ezetimibe-statin combination therapy with a statin- or placebo-controlled arm and reported at least one MACE, stratified by diabetes status, were included in the meta-analysis and meta-regression. A total of seven trials with 28,191 enrolled patients (mean age, 63.6 years; 75.1% men; 7,298 with diabetes [25.9%]; mean follow-up, 5 years) were analysed. MACEs stratified by diabetes were obtained from the published data (two trials) or through direct contact (five trials). No significant heterogeneity was observed among studies (I²=14.7%, P=0.293). Ezetimibe was associated with a greater reduction of MACE risk in subjects with diabetes than in those without diabetes (pooled relative risk, 0.84 vs. 0.93; P(heterogeneity)=0.012). In the meta-regression analysis, the presence of diabetes was associated with a...Continue Reading

References

Apr 6, 1996·Lancet·H C Gerstein, S Yusuf
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Sep 6, 2003·BMJ : British Medical Journal·Julian P T HigginsDouglas G Altman
Oct 16, 2004·Current Cardiology Reports·Shailendra B Patel
Sep 4, 2008·The New England Journal of Medicine·Richard PetoRobert Califf
Sep 4, 2008·The New England Journal of Medicine·Jeffrey M DrazenGregory D Curfman
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Jul 23, 2009·BMJ : British Medical Journal·David MoherUNKNOWN PRISMA Group
Mar 17, 2010·The New England Journal of Medicine·Henry N GinsbergRobert P Byington
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Nov 15, 2011·Circulation Journal : Official Journal of the Japanese Circulation Society·Tomas KovarnikAles Linhart
May 11, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·George N KouvelosHaralampos J Milionis
Aug 31, 2013·Diabetes & Metabolism Journal·Sung-Woo Park
Nov 19, 2013·Journal of the American College of Cardiology·Neil J StoneUNKNOWN American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Jul 23, 2014·Journal of Pharmacological Sciences·Li QinDuan-Fang Liao
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jul 21, 2015·International Journal of Cardiology·Kwang Kon KohEak Kyun Shin
Aug 25, 2015·International Journal of Cardiology·Gianluigi SavaresePasquale Perrone-Filardi
Jun 9, 2016·Korean Circulation Journal·UNKNOWN Committee for the Korean Guidelines for the Management of Dyslipidemia
Aug 28, 2016·European Heart Journal·Alberico L CatapanoUNKNOWN ESC Scientific Document Group
Jan 17, 2017·Journal of Evaluation in Clinical Practice·Yutong FeiFrederick A Spencer

❮ Previous
Next ❯

Citations

Jun 28, 2018·Endocrinology and Metabolism·Eun Jung RheeWon Young Lee
Sep 1, 2019·Current Pharmaceutical Design·Alessandra VecchiéAldo Bonaventura
Oct 9, 2019·Expert Opinion on Biological Therapy·Daniel SteffensUrsula Rauch-Kröhnert
Jan 16, 2019·Expert Review of Clinical Pharmacology·Angelo Maria PattiAli A Rizvi
Aug 7, 2021·Diabetes & Metabolism Journal·Kyu Yeon HurUNKNOWN Committee of Clinical Practice Guidelines, Korean Diabetes Association

❮ Previous
Next ❯

Software Mentioned

SHARP
STATA
IMPROVE
IT

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.